cACLD in Patients With Alcohol Use Disorder in the Hospital Detoxification Unit

Condition(s) studied

Investigational drug(s) / intervention(s)

Screening of compensated advance chronic liver disease: The tests performed will include a general blood analysis to evaluate liver and kidney function, an assessment of the prevalence of metabolic diseases such as obesity, hypertension, or diabetes, an abdominal ultrasound, and elastography to assess liver stiffness. Another intervention to be studied is whether the request for diagnostic tests to evaluate liver disease, as well as the visit of the hepatologist during hospitalization in the detoxification unit, influences subsequent alcohol abstinence. To this end, abstinence will be assessed six months after admission to the alcohol detoxification unit and compared with a retrospective cohort of patients admitted to the detoxification unit one year ago, in whom no liver disease evaluation was conducted neither information of potencial liver damage was offered by hepatologist and the intervention was carried out only by the psychiatrists responsible for the unit.

Study summary

The aim of this study is to conduct a quick assessment of potential liver damage caused by chronic alcohol consumption. Taking advantage of the patient's admission to a specialized detoxification unit, several tests will be performed to determine the extent of liver damage through blood tests, ultrasound, and FibroScan

Eligibility

Primary outcome measure(s)

• Prevalence of advanced chronic liver disease in patients who are electively admitted to the hospital alcohol detoxification unit — 5 days
  Prevalence of pathological findings in the fibroscan that suggest compensated chronic liver disease

Trial sites (1)

More Corporacion Parc Tauli trials in Spain

Other trials for the same condition